NMN and NR Evidence Guide: Human Studies, Labels and US Regulatory Status
On this page
NMN and NR have been studied as NAD+ precursors, but a research dose is not a personalized supplement recommendation. Human trials differ in participants, product, dose, duration and outcome. The NIH Office of Dietary Supplements reports no established Daily Value for these compounds and notes the current US restriction on marketing NMN as a dietary supplement.
Quick answer
This guide helps you read a label against published human studies. It does not select a dose, predict longevity, or treat an NAD+ blood result as a health outcome.
What NMN and NR are
Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are related to niacin metabolism and have been investigated as precursors used by the body in NAD+ pathways. Raising a blood NAD+ measure is a biomarker result; it does not by itself prove prevention of aging, disease, disability or death.
Use the Supplement Stack Calculator only to inventory products and overlapping ingredients, not to decide medical necessity.
Human study-dose examples
| Compound | Published regimen | Study context | What it is not |
|---|---|---|---|
| NMN | 250 mg/day for 12 weeks | Small randomized trial in healthy adults; blood NAD+ and safety measures | A universal dose or longevity outcome |
| NR | 100, 300 or 1000 mg/day for 8 weeks | Randomized trial in healthy overweight adults; NAD+ metabolites and safety | A dose-response proof for clinical benefit |
| NR | 1000 mg twice daily for 12 weeks | Randomized trial in obese men; insulin sensitivity and lipid outcomes | Evidence that more is better |
These rows document trial exposure only. They are not dose instructions, and the populations and products cannot be assumed to match an individual reader.
What the evidence does and does not show
Some trials show changes in NAD+ metabolites and selected exploratory outcomes. Sample sizes are often small and follow-up is short relative to claims about aging. Findings can be null, inconsistent or limited to a specific population. A biomarker change should not be rewritten as proof of longer life, disease prevention or improved function.
How to compare a product label
- Identify the exact compound: NR, NMN, niacinamide or another ingredient.
- Record the amount per serving and the number of servings, rather than relying on front-label language.
- Check whether a blend hides individual amounts.
- Compare the product form and daily exposure with the actual research paper, not a marketing summary.
- Look for third-party testing information, lot identification and contact details; none proves clinical benefit.
US regulatory status
The NIH ODS fact sheet states that FDA determined in November 2022 that NMN may not be legally marketed as a dietary supplement because it had been authorized for investigation as a new drug. Regulatory status can change, so verify current FDA information and do not assume that a product offered for sale is lawful, effective or independently tested.
Questions before using a product
- Does the product interact with medicines, pregnancy, breastfeeding, liver or kidney disease, surgery or cancer treatment?
- Is the claimed benefit a measured clinical outcome or only a laboratory marker?
- Does the cited trial use the same compound, dose, duration and population?
- What adverse effects, withdrawals and conflicts of interest were reported?
Frequently asked questions
What is the established daily dose of NMN or NR?
No universally established daily value or individualized dose is supplied by this guide. Study regimens are research exposures, not recommendations.
Does higher blood NAD+ mean slower aging?
Not necessarily. A biomarker change is not the same as a validated longevity outcome.
Can NMN be sold as a dietary supplement in the United States?
NIH ODS reports FDA determined that it may not legally be marketed as a dietary supplement; verify current FDA status because regulatory decisions can change.
Sources
- NIH ODS: Niacin - Health Professional Fact Sheet
- NMN 250 mg/day randomized trial
- NR 100, 300 and 1000 mg/day randomized trial
- NR 1000 mg twice daily randomized trial
Sources checked 2026-10-07. No individual dose or treatment conclusion is provided.